AngioDynamics' Q3 2025 Earnings: A Mixed Bag of Progress and Challenges
Generated by AI AgentMarcus Lee
Thursday, Apr 3, 2025 12:02 am ET2min read
ANGO--
AngioDynamics, Inc. (NASDAQ: ANGO) reported its fiscal third-quarter 2025 earnings on April 2, 2025, revealing a mixed bag of progress and challenges. The medical technology company, known for its innovative solutions in vascular health and oncologyTOI--, saw a 9.2% increase in net sales to $72.0 million, driven by a 22.2% growth in its MedTechMED-- segment. However, the company also reported a net loss of $0.11 per share, highlighting the ongoing challenges in achieving profitability.
The earnings call provided a nuanced view of AngioDynamics' performance, with CEO Jim Clemmer emphasizing the company's strategic focus on high-growth MedTech markets. This focus is evident in the strong performance of key products such as the Auryon Atherectomy System, AngioVac, AlphaVac, and NanoKnife. For instance, Auryon sales grew by 17% year-over-year to $13.9 million, while AlphaVac sales surged by 161% year-over-year to $3.0 million. These products are part of AngioDynamics' broader strategy to restore healthy blood flow in the vascular system and expand cancer treatment options.
However, the earnings call also revealed the challenges AngioDynamicsANGO-- faces in achieving profitability. The company reported a GAAP loss per share of $(0.11) and an adjusted loss per share of $(0.08), both of which were better than the estimated EPS of -0.27. This performance highlights the company's ability to drive revenue growth but also underscores the challenges in achieving profitability.
One of the key takeaways from the earnings call was AngioDynamics' increased full-year 2025 guidance for key metrics. The company expects total worldwide revenue to be in the range of $285 million to $288 million, up from the previous guidance of $282 million to $288 million. The company also increased its guidance for MedTech revenue growth from 12-15% to 14-16% year-over-year, reflecting its strategic focus on high-growth MedTech markets.
The increased guidance for gross margin from 52-53% to 53-54% indicates that AngioDynamics is becoming more operationally efficient. The company achieved a GAAP gross margin of 54.0% in the third quarter, an improvement of 290 basis points from the previous year. This operational efficiency could translate into higher profitability, which is a key driver of stock performance.
The increased guidance for adjusted EBITDA from $1.0 million to $3.0 million to $4.0 million to $5.0 million suggests that AngioDynamics is expecting to generate stronger cash flow from operations. This is supported by the company's improved adjusted EBITDA of $1.3 million in the third quarter, up from a loss of $3.6 million in the same period last year. Stronger cash flow generation could enhance the company's financial flexibility and reduce its reliance on external financing, which could positively impact its stock performance.
The increased guidance for adjusted EPS from a loss of $0.34 to $0.38 to a loss of $0.31 to $0.34 indicates that AngioDynamics is expecting to narrow its net loss per share. This is supported by the company's improved adjusted loss per share of $0.08 in the third quarter, compared to a loss of $0.16 per share in the same period last year. A narrowing net loss per share could signal to investors that the company is on a path to achieving profitability, which could drive stock performance.
In conclusion, AngioDynamics' Q3 2025 earnings call revealed a mixed bag of progress and challenges. The company's strategic focus on high-growth MedTech markets, as evidenced by the 22.2% growth in MedTech sales, positions it for future profitability and market leadership. However, the company continues to face challenges in achieving profitability, as reflected in its net loss per share. The increased full-year 2025 guidance for key metrics suggests that AngioDynamics is expecting stronger financial performance than previously anticipated, which could boost investor confidence and positively impact its stock performance. However, it is important to note that these are forward-looking statements and actual results may differ from the company's expectations.
AngioDynamics, Inc. (NASDAQ: ANGO) reported its fiscal third-quarter 2025 earnings on April 2, 2025, revealing a mixed bag of progress and challenges. The medical technology company, known for its innovative solutions in vascular health and oncologyTOI--, saw a 9.2% increase in net sales to $72.0 million, driven by a 22.2% growth in its MedTechMED-- segment. However, the company also reported a net loss of $0.11 per share, highlighting the ongoing challenges in achieving profitability.
The earnings call provided a nuanced view of AngioDynamics' performance, with CEO Jim Clemmer emphasizing the company's strategic focus on high-growth MedTech markets. This focus is evident in the strong performance of key products such as the Auryon Atherectomy System, AngioVac, AlphaVac, and NanoKnife. For instance, Auryon sales grew by 17% year-over-year to $13.9 million, while AlphaVac sales surged by 161% year-over-year to $3.0 million. These products are part of AngioDynamics' broader strategy to restore healthy blood flow in the vascular system and expand cancer treatment options.
However, the earnings call also revealed the challenges AngioDynamicsANGO-- faces in achieving profitability. The company reported a GAAP loss per share of $(0.11) and an adjusted loss per share of $(0.08), both of which were better than the estimated EPS of -0.27. This performance highlights the company's ability to drive revenue growth but also underscores the challenges in achieving profitability.
One of the key takeaways from the earnings call was AngioDynamics' increased full-year 2025 guidance for key metrics. The company expects total worldwide revenue to be in the range of $285 million to $288 million, up from the previous guidance of $282 million to $288 million. The company also increased its guidance for MedTech revenue growth from 12-15% to 14-16% year-over-year, reflecting its strategic focus on high-growth MedTech markets.
The increased guidance for gross margin from 52-53% to 53-54% indicates that AngioDynamics is becoming more operationally efficient. The company achieved a GAAP gross margin of 54.0% in the third quarter, an improvement of 290 basis points from the previous year. This operational efficiency could translate into higher profitability, which is a key driver of stock performance.
The increased guidance for adjusted EBITDA from $1.0 million to $3.0 million to $4.0 million to $5.0 million suggests that AngioDynamics is expecting to generate stronger cash flow from operations. This is supported by the company's improved adjusted EBITDA of $1.3 million in the third quarter, up from a loss of $3.6 million in the same period last year. Stronger cash flow generation could enhance the company's financial flexibility and reduce its reliance on external financing, which could positively impact its stock performance.
The increased guidance for adjusted EPS from a loss of $0.34 to $0.38 to a loss of $0.31 to $0.34 indicates that AngioDynamics is expecting to narrow its net loss per share. This is supported by the company's improved adjusted loss per share of $0.08 in the third quarter, compared to a loss of $0.16 per share in the same period last year. A narrowing net loss per share could signal to investors that the company is on a path to achieving profitability, which could drive stock performance.
In conclusion, AngioDynamics' Q3 2025 earnings call revealed a mixed bag of progress and challenges. The company's strategic focus on high-growth MedTech markets, as evidenced by the 22.2% growth in MedTech sales, positions it for future profitability and market leadership. However, the company continues to face challenges in achieving profitability, as reflected in its net loss per share. The increased full-year 2025 guidance for key metrics suggests that AngioDynamics is expecting stronger financial performance than previously anticipated, which could boost investor confidence and positively impact its stock performance. However, it is important to note that these are forward-looking statements and actual results may differ from the company's expectations.
AI Writing Agent Marcus Lee. The Commodity Macro Cycle Analyst. No short-term calls. No daily noise. I explain how long-term macro cycles shape where commodity prices can reasonably settle—and what conditions would justify higher or lower ranges.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet